Pfizer Inc (PFE.N)
35.64USD
18 May 2018
$-0.07 (-0.20%)
$35.71
$35.58
$35.74
$35.43
4,743,555
7,830,805
$39.43
$31.67
About
Overall
| Beta: | 0.99 |
| Market Cap(Mil.): | $214,682.30 |
| Shares Outstanding(Mil.): | 5,955.13 |
| Dividend: | 0.32 |
| Yield (%): | 3.55 |
Financials
| PFE.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 26.26 | 30.95 | 32.75 |
| EPS (TTM): | 1.37 | -- | -- |
| ROI: | 6.00 | 14.84 | 14.38 |
| ROE: | 13.80 | 16.34 | 16.07 |
Johnson & Johnson scraps Alzheimer's trials on safety concerns
Johnson and Johnson said it would stop mid-stage trials testing its experimental Alzheimer's drug after observing safety issues, the latest drugmaker to abandon developing treatments for the memory-robbing disease.
Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod
Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.
UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod
* Shares of Amgen, JNJ fall in afternoon trading (Adds analyst comments, updates shares)
FDA approves Pfizer's biosimilar of Amgen's Epogen
May 15 The U.S. Food and Drug Administration on Tuesday approved Pfizer Inc's biosimilar of Amgen Inc's anemia treatment Epogen.
FDA says Mylan's EpiPen is in shortage in U.S.
U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment. | Video
FDA says Mylan's EpiPen is in shortage in U.S.
U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment. | Video
UPDATE 3-FDA says Mylan's EpiPen is in shortage in U.S.
May 9 U.S. regulators said on Wednesday that Mylan NV's EpiPen products are in shortage due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.
Drugmaker GSK rings in more change as CFO heads for exit in 2019
LONDON GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.
Drugmaker GSK rings in more change as CFO heads for exit in 2019
LONDON GlaxoSmithKline Plc , Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.
UPDATE 1-Drugmaker GSK rings in more change as CFO heads for exit in 2019
LONDON, May 9 GlaxoSmithKline Plc, Britain's biggest drugmaker, faces more top management change with Chief Financial Officer Simon Dingemans set to retire next year.
Competitors
| Price | Chg | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $124.24 | +0.39 |
| Novartis AG (NOVN.S) | CHF77.00 | -0.64 |
| Merck & Co., Inc. (MRK.N) | $59.14 | +0.07 |
| Roche Holding Ltd. (ROG.S) | CHF224.55 | +0.55 |
| Roche Holding Ltd. (RO.S) | CHF229.20 | +1.00 |
| Abbott Laboratories (ABT.N) | $61.71 | +0.65 |
| Bayer AG (BAYGn.DE) | €104.36 | -0.14 |
| Bayer AG (BAYE.F) | -- | -- |
| Sanofi SA (SASY.PA) | €66.44 | +0.32 |
| AstraZeneca plc (AZN.L) | 5,241.00 | -104.00 |
Estimates